{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:38:08Z","timestamp":1789558688709,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.amjoto.2025.104705","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T14:23:27Z","timestamp":1753021407000},"page":"104705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Analysis of adverse reaction characteristics of four biologics for the treatment of chronic sinusitis with nasal polyps: A descriptive analysis from WHO-VigiAccess"],"prefix":"10.1016","volume":"46","author":[{"given":"Xiaobi","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.amjoto.2025.104705_bb0005","article-title":"Proposal for a new diagnostic-therapeutic algorithm in chronic rhinosinusitis with nasal polyps","volume":"94","author":"Gelardi","year":"2023","journal-title":"Acta Biomed"},{"issue":"6","key":"10.1016\/j.amjoto.2025.104705_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061379","article-title":"FcRn-dependent transcytosis of monoclonal antibody in human nasal epithelial cells in vitro: a prerequisite for a new delivery route for therapy?","volume":"20","author":"Bequignon","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104705_bb0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40463-023-00626-9","article-title":"Canadian multidisciplinary expert consensus on the use of biologics in upper airways: a Delphi study","volume":"52","author":"Thamboo","year":"2023","journal-title":"J Otolaryngol Head Neck Surg"},{"issue":"2","key":"10.1016\/j.amjoto.2025.104705_bb0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.anai.2022.04.004","article-title":"Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps","volume":"129","author":"Borish","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"10.1016\/j.amjoto.2025.104705_bb0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000519228","article-title":"Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"10.1016\/j.amjoto.2025.104705_bb0030","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps","volume":"392","author":"Lipworth","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.amjoto.2025.104705_bb0035","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jaci.2020.01.020","article-title":"Biologics for chronic rhinosinusitis with nasal polyps","volume":"145","author":"Bachert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.amjoto.2025.104705_bb0040","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s12325-025-03120-y","article-title":"Real-world outcomes following biologic initiation in US patients with chronic rhinosinusitis with nasal polyps","volume":"42","author":"Peters","year":"2025","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.amjoto.2025.104705_bb0045","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL)","volume":"78","author":"De Corso","year":"2023","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.amjoto.2025.104705_bb0050","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/lio2.758","article-title":"Clinical characteristics of patients with CRSwNP with intensely high eosinophil level","volume":"7","author":"Ma","year":"2022","journal-title":"Laryngoscope Investig Otolaryngol"},{"issue":"11","key":"10.1016\/j.amjoto.2025.104705_bb0055","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/j.jaip.2024.09.021","article-title":"Efficacy of biologics in NSAID-ERD: united airways from the nose to the bronchi","volume":"12","author":"Buchheit","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.amjoto.2025.104705_bb0060","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.amjoto.2025.104705_bb0065","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fphar.2020.00315","article-title":"Intravitreal anti-VEGF drugs and signals of dementia and Parkinson-like events: analysis of the VigiBase database of spontaneous reports","volume":"11","author":"Sultana","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.amjoto.2025.104705_bb0070","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eplepsyres.2017.06.007","article-title":"Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"135","author":"Rahman","year":"2017","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.amjoto.2025.104705_bb0075","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1172\/JCI129697","article-title":"The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcgamma receptors","volume":"130","author":"Balbino","year":"2020","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.amjoto.2025.104705_bb0080","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/lary.31305","article-title":"Real-world adverse events after type 2 biologic use in chronic rhinosinusitis with nasal polyps","volume":"134","author":"Dorling","year":"2024","journal-title":"Laryngoscope"},{"key":"10.1016\/j.amjoto.2025.104705_bb0085","doi-asserted-by":"crossref","first-page":"1080951","DOI":"10.3389\/falgy.2023.1080951","article-title":"Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?","volume":"4","author":"Van Broeck","year":"2023","journal-title":"Front Allergy"},{"issue":"12","key":"10.1016\/j.amjoto.2025.104705_bb0090","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.jaip.2024.09.015","article-title":"Dupilumab versus mepolizumab for chronic rhinosinusitis with nasal polyposis: an indirect treatment comparison","volume":"12","author":"Hopkins","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.amjoto.2025.104705_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5604\/01.3001.0054.9674","article-title":"Results of personalized biological therapy in patients with chronic rhinosinusitis with nasal polyps and severe uncontrolled bronchial asthma - real-life study","volume":"79","author":"Jura-Szoltys","year":"2025","journal-title":"Otolaryngol Pol"},{"issue":"8","key":"10.1016\/j.amjoto.2025.104705_bb0100","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/1744666X.2023.2218617","article-title":"Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making","volume":"19","author":"Otten","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"10.1016\/j.amjoto.2025.104705_bb0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/alr.23090","article-title":"International consensus statement on allergy and rhinology: allergic rhinitis - 2023","volume":"13","author":"Wise","year":"2023","journal-title":"Int Forum Allergy Rhinol"},{"issue":"5","key":"10.1016\/j.amjoto.2025.104705_bb0110","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.amjoto.2025.104705_bb0115","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/JAA.S275039","article-title":"Targeting TSLP in asthma","volume":"15","author":"Parnes","year":"2022","journal-title":"J Asthma Allergy"},{"issue":"9","key":"10.1016\/j.amjoto.2025.104705_bb0120","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s12325-023-02573-3","article-title":"Analyses of Dupilumab-related ocular adverse drug reactions using the WHO\u2019S VigiBase","volume":"40","author":"Hirai","year":"2023","journal-title":"Adv Ther"},{"issue":"5","key":"10.1016\/j.amjoto.2025.104705_bb0125","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15059","article-title":"Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-center experience","volume":"34","author":"Napolitano","year":"2021","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.amjoto.2025.104705_bb0130","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.jid.2023.12.018","article-title":"IL-26 potentiates type 2 skin inflammation in the presence of IL-1beta","volume":"144","author":"Bier","year":"2024","journal-title":"J Invest Dermatol"},{"issue":"sup3","key":"10.1016\/j.amjoto.2025.104705_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/09546634.2018.1551608","article-title":"Chronic spontaneous urticaria treated with omalizumab: report of two cases","volume":"29","author":"Malara","year":"2018","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.amjoto.2025.104705_bb0140","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaci.2014.08.025","article-title":"The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy","volume":"135","author":"Namazy","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.amjoto.2025.104705_bb0145","doi-asserted-by":"crossref","first-page":"2304027","DOI":"10.1080\/09546634.2024.2304027","article-title":"Injection site reactions after dupilumab or tralokinumab for atopic dermatitis","volume":"35","author":"Martora","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.amjoto.2025.104705_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.920066","article-title":"Severe pediatric asthma therapy: Mepolizumab","volume":"10","author":"Ullmann","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.amjoto.2025.104705_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102076","article-title":"Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"61","author":"Zhang","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"14\u201315","key":"10.1016\/j.amjoto.2025.104705_bb0160","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/1750743X.2024.2386899","article-title":"Investigators a: Effects of benralizumab in patients with severe eosinophilic asthma (SEA): a plain language summary of the ANANKE study","volume":"16","author":"Canonica","year":"2024","journal-title":"Immunotherapy"},{"issue":"14","key":"10.1016\/j.amjoto.2025.104705_bb0165","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjoto.2025.104705_bb0170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070925001085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070925001085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:02:54Z","timestamp":1756368174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196070925001085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0196070925001085"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2025.104705","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of adverse reaction characteristics of four biologics for the treatment of chronic sinusitis with nasal polyps: A descriptive analysis from WHO-VigiAccess","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2025.104705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104705"}}